Summary
39 / 100 · Bulios Score
What speaks for it
- Revenue grew by 31% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Analysts expect revenue to fall by 27% this fiscal year.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 41% a year over 5 years. Over the last 3 years it grew by 31% a year. For the next fiscal year analysts expect revenue to fall by 27%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $987.8M.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 21
- Hold 15
- Sell 3
Today's price within the analysts' price targets
The average target of $211.55 is 19% above today's price. 54% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Bank Servicing, Consumer, Net 48%
- Subscription and Circulation, Stablecoin 19%
- Subscription and Circulation, Blockchain Infrastructure Service 9.8%
- Subscription and Circulation, Other 8.0%
- Bank Servicing, Institutional 6.9%
- Other 7.9%
By region
- UNITED STATES 84%
- Rest of the World 16%
Bank Servicing, Consumer, Net brings in 48% of revenue. Subscription and Circulation, Other grew fastest, by 68% a year.
Segments in detail